Clinical trials: Metastatic Renal Cancer
Renal Cell Carcinoma, Non-small Cell Lung Cancer
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, immune response and preliminary anti-tumor activity of RO7515629 alone in participants with advanced or metastatic solid tumors expressing…
- Conditions
- Renal Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer
- Trial name
- NCT05769959
- Testing
- RO7515629, tocilizumab
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer, Gastric Cancer
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
This is a Phase 1, open-label, 2-part, multi-center study evaluating the safety, tolerability, PK, pharmacodynamics (PD), immunogenicity, and antitumor activity of CUE-102 intravenous (IV) monotherapy in HLA-A*0201 positive…
- Conditions
- Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- NCT05360680
- Testing
- CUE-102
- Where
- 15 sites in United States
- Volunteers
- 42 people
- Sponsor
- Cue Biopharma
Urothelial Carcinoma, Urothelial Carcinoma Bladder
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.
- Conditions
- Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter
- Trial name
- NCT03606174
- Testing
- Sitravatinib, Nivolumab, Pembrolizumab
- Where
- 36 sites in United States
- Volunteers
- 260 people
- Sponsor
- Mirati Therapeutics Inc.
Metastatic Renal Cell Carcinoma
Prospective Translational Study Investigating Predictors of Outcome in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab (I-Rene Trial)
Prospective translational study investigating predictors of outcome in metastatic renal cell carcinoma patients treated with Nivolumab (I-Rene trial)
- Trial name
- I-Rene (NCT04891055)
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Renal Cell Carcinoma (Kidney Cancer), Metastatic Renal Cell Carcinoma
Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma
The aim of the study is to evaluate the impact of digital monitoring of self-reported symptoms (PROs) on the adjustment of treatment management in patients treated with cabozantinib plus nivolumab for advanced clear cell renal…
- Conditions
- Renal Cell Carcinoma (Kidney Cancer), Metastatic Renal Cell Carcinoma, Locally Advanced
- Trial name
- CANIQOL (NCT07028125)
- Testing
- cabozantinib and nivolumab
- Where
- 19 sites in France
- Volunteers
- 83 people
- Sponsor
- Centre Francois Baclesse
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal…
- Trial name
- NCT02231749
- Testing
- Nivolumab, Ipilimumab, Sunitinib
- Where
- 189 sites in United States, Argentina and 26 more
- Volunteers
- 1,096 people
- Sponsor
- Bristol-Myers Squibb
Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma
Phase 1/2 study evaluates the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CD70/CAIX CAR-NK cells after fludarabine/cyclophosphamide lymphodepletion in adults with advanced or metastatic clear…
- Trial name
- DUAL-NK RCC (NCT07551349)
- Testing
- EB-701/CA9-NK, Fludarabine
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Metastatic Renal Cell Carcinoma
Sequential Therapy in Metastatic Renal Cell Carinoma
Sequential therapy with BEvacizumab, RAd001 (everolimus) and Tyrosinekinase inhibitors (TKI) in metastatic renal cell carcinoma (mRCC)
- Trial name
- BERAT (NCT01731158)
- Testing
- Avastin in combination with Roferon-A, Afinitor, TKI: Sutent, Nexavar or Votrient
- Where
- 13 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Central European Society for Anticancer Drug Research
Pancreatic Cancer, Hepatocellular Cancer
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors.
- Conditions
- Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer
- Trial name
- NCT05070247
- Testing
- TAK-500, Pembrolizumab, Tocilizumab
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Takeda
Metastatic Renal Cell Carcinoma
A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.
Sunitinib given at 50 mg/day on schedule 4/2 (4 weeks on treatment, 2 weeks off) is the standard care for first-line treatment of metastatic renal cell carcinoma, but the schedule was reported with a high rate of dose reduction…
- Trial name
- NCT02398552
- Testing
- Sunitinib
- Where
- 6 sites in China
- Volunteers
- 80 people
- Sponsor
- Peking University Cancer Hospital & Institute
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT00030498
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma, Neoplasm Metastases
Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
The purpose of this research study is to determine if the combination of sunitinib and gemcitabine is effective in treating patients with metastatic renal cell carcinoma. The safety of this combination will also be studied.
- Trial name
- NCT00556049
- Testing
- Gemcitabine, Sunitinib
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Massachusetts General Hospital
Kidney Neoplasms
Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
The primary purpose of this protocol is to determine the activity of AG 013736 in patients with metastatic renal cell cancer who have received 1 prior cytokine-based therapy.
- Trial name
- NCT00076011
- Testing
- Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor
- Where
- 9 sites in United States, France and 1 more
- Volunteers
- 52 people
- Sponsor
- Pfizer
Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
This phase II trial studies how well atezolizumab when given with glycosylated recombinant human interleukin-7 (CYT107) works in treating patients with urothelial carcinoma that has spread to nearby tissue or lymph nodes (locally…
- Conditions
- Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma
- Trial name
- NCT03513952
- Testing
- Atezolizumab, Biopsy, Biospecimen Collection
- Where
- 9 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma, Kidney Neoplasm
Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
The purpose of the open-label INDIGO-study is to examine whether a first line individualized treatment strategy based on DNA and RNA analyses from the patient's tumor is feasible.
- Conditions
- Metastatic Renal Cell Carcinoma, Kidney Neoplasm, Urologic Neoplasms, Urogenital Neoplasms
- Trial name
- INDIGO (NCT04644432)
- Testing
- Medication (A specification is listed under each arm), Patient reported outcomes measurement
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Herlev and Gentofte Hospital
Advanced Malignancies
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01949 when given in combination with immune therapies in participants with advanced or metastatic malignancies.
- Trial name
- NCT03241173
- Testing
- INCAGN01949, Nivolumab, Ipilimumab
- Where
- 15 sites in United States
- Volunteers
- 52 people
- Sponsor
- Incyte Biosciences International Sàrl
Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
App-Based Mindfulness Intervention for the Improvement of Quality of Life in Patients With Metastatic Renal Cell Cancer
This trial tests the feasibility of an application (app)-based mindfulness intervention and its effect on improving quality of life in patients with renal cell cancer that has spread to other places in the body (metastatic).
- Trial name
- NCT04788095
- Testing
- Behavioral Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- City of Hope Medical Center
Renal Cell Carcinoma
Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent
The Sutent® Observational Study is being proposed to assess the real-world usage patterns and effectiveness and tolerability of treatment of Indian patients with advanced renal cell cancer with Sutent®.
- Trial name
- NCT00836745
- Testing
- Non Interventional
- Where
- 7 sites in India
- Volunteers
- 36 people
- Sponsor
- Pfizer
Renal Cancer Metastatic
A Study of Anti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal Carcinoma
Phase II clinical trial to investigate the safety, clinical activity and toxicity of combinations of D-CIK and low dose anti-PD-1 antibody in patients with metastatic renal cell carcinoma treated with axitinib.
- Trial name
- NCT03736330
- Testing
- Combinations treatment
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Metastatic Renal Cancer, Stage III Renal Cell Cancer
Safety and Compliance of Renal Cancer Patients Treated by Non-IV Drugs
Generally, in the trials, an observant patient is described as correctly taking 90 to 100% of the prescribed doses. Here, the 80% compliance rate will be the cut-off between observant and non-observant patients.
- Trial name
- TOPTACOS (NCT03630692)
- Testing
- observance of oral drug treatment
- Where
- 14 sites in France
- Volunteers
- 158 people
- Sponsor
- Institut Cancerologie de l'Ouest
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.